Pandemics/Epidemics (Free)
Search All Applications in Pandemics/Epidemics (Free)
Application US20200282046
Published 2020-09-10
Betacoronavirus Mrna Vaccine
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1.-135. (canceled)
- 136. A method comprising administering to a subject a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a Betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle in an effective amount to induce in the subject an immune response to the Betacoronavirus S protein or S protein subunit.
- 154. A method comprising administering to a subject an mRNA comprising a 5′ cap analog, a 5′ untranslated region, an open reading frame encoding a BetaCoV S protein or S protein subunit, a 3′ untranslated region, and a poly(A) tail formulated in a lipid nanoparticle in an effective amount to induce in the subject an immune response to the BetaCoV S protein or S protein subunit, wherein the lipid nanoparticle comprises 20-60 mol % ionizable cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % PEG-modified lipid.
